CEO & Executive Consultant
KC Biopharmaceutical Consulting
Dr. Kamali Chance is CEO & an Excutive Conultant at KC Biopharma.. She is an accomplished executive with more than 25+ years of extensive experience developing both global and country-specific regulatory strategies and clinical development plans. At KC Biopharma she assists clients in developing comprehensive clinical development plans to meet requirements in multiple countries and regions, including successfully spearheading INDs, NDAs, and BLAs and managing processes with the FDA and EMA.
Throughout her journey, Dr. Chance has helped drug developers bring pharmaceutical and biotech products to the US and EU markets. She has also supported development from early and late stages and from conceptual design to product launch at various companies.
Dr. Chance’s profession in regulatory sciences began with several roles at Banner Pharmacaps, DSM Pharmaceuticals, Synthon, and Quintiles (now IQVIA), where at the end of her successful tenure, she held the position of Vice President and Head of Global Biosimilars Regulatory Strategy. In 2018, before joining Amador, Dr. Chance created KC Biopharma Consulting, serving as its President, CEO, and Executive Consultant.
Dr. Chance holds a PhD in Nutrition and Nutritional Biochemistry from the University of North Carolina in Greensboro, and a Master of Public Health from the University of North Carolina in Chapel Hill. She also has Regulatory Affairs Certification from the Regulatory Affairs Professional Society.
Over the years, Dr. Chance has published more than 20 articles and given numerous presentations at a variety of national and international conferences as well as other industry forums.
Disclosure information not submitted.
Is Animal Testing Really No Longer Needed for Drug Development?
Thursday, October 5, 2023
3:30 PM - 4:30 PM EDT